FIH-1 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $84.00 $301.00 $374.00 $779.00 | 25 | |
Dimethyloxaloylglycine (DMOG) acts as a potent inhibitor of factor inhibiting hypoxia-inducible factor-1 (FIH-1), influencing the stability of HIF-1α. Its unique molecular structure allows for specific binding interactions with the FIH-1 active site, effectively disrupting hydroxylation processes. DMOG's ability to mimic the effects of hypoxia leads to altered cellular responses, enhancing the transcriptional activity of HIF-1. This compound's kinetic properties enable it to modulate pathways involved in oxygen sensing and metabolic adaptation. | ||||||
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $255.00 | ||
Deferoxamine is an iron chelator that reduces the availability of iron, which is required for FIH-1's enzymatic activity. By limiting iron availability, it indirectly inhibits FIH-1, promoting HIF-1α stabilization and increased transcriptional activity. | ||||||
L-Mimosine | 500-44-7 | sc-201536A sc-201536B sc-201536 sc-201536C | 25 mg 100 mg 500 mg 1 g | $36.00 $88.00 $220.00 $436.00 | 8 | |
L-Mimosine inhibits FIH-1 activity by competing with HIF-1α for hydroxylation, preventing its degradation under normoxic conditions. This leads to the indirect stabilization of HIF-1α and enhanced transcriptional activity. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
Cobalt chloride can mimic hypoxic conditions by displacing iron from FIH-1's active site, inhibiting FIH-1's hydroxylation of HIF-1α, and indirectly activating HIF-1α by preventing its degradation under normoxic conditions. | ||||||
L-Ascorbic acid, free acid | 50-81-7 | sc-202686 | 100 g | $46.00 | 5 | |
L-Ascorbic acid enhances HIF-1α hydroxylation by providing the necessary cofactor for FIH-1. Increased ascorbate levels can indirectly inhibit HIF-1α by supporting FIH-1 function and promoting its degradation under normoxic conditions. | ||||||
α-Ketoglutaric Acid | 328-50-7 | sc-208504 sc-208504A sc-208504B sc-208504C sc-208504D sc-208504E sc-208504F | 25 g 100 g 250 g 500 g 1 kg 5 kg 16 kg | $33.00 $43.00 $63.00 $110.00 $188.00 $738.00 $2091.00 | 2 | |
α-KG is a cofactor required for FIH-1 activity. Elevated levels of α-KG can support FIH-1 function, indirectly contributing to HIF-1α inhibition by promoting its hydroxylation and degradation under normoxic conditions. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin is an HSP90 inhibitor that indirectly affects FIH-1 stability. By inhibiting HSP90, geldanamycin promotes FIH-1 degradation, reducing its activity, and indirectly stabilizing HIF-1α under normoxic conditions. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK/STAT inhibitors like ruxolitinib disrupt the JAK/STAT pathway, which can activate HIF-1α expression. By inhibiting this pathway, ruxolitinib can indirectly downregulate HIF-1α expression and activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly affects HIF-1α translation. By inhibiting mTOR, rapamycin can indirectly inhibit HIF-1α expression by suppressing its translation under normoxic conditions. | ||||||